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This study compared genetic nurse counsellors with standard services for breast cancer genetic risk counselling services in two
regional genetics centres, in Grampian region, North East Scotland and in Cardiff, Wales. Women referred for genetic counselling
were randomised to an initial genetic counselling appointment with either a genetic nurse counsellor (intervention) or a clinical
geneticist (current service, control). Participants completed postal questionnaires before, immediately after the counselling episode
and 6 months later to assess anxiety, general health status, perceived risk and satisfaction. A parallel economic evaluation explored
factors influencing cost-effectiveness. The two concurrent randomised controlled equivalence trials were conducted and analysed
separately. In the Grampian trial, 289 patients (193 intervention, 96 control) and in the Wales trial 297 patients (197 intervention and
100 control) returned a baseline questionnaire and attended their appointment. Analysis suggested at least likely equivalence in
anxiety (the primary outcome) between the two arms of the trials. The cost per counselling episode was d11.54 less for nurse-based
care in the Grampian trial and d12.50 more for nurse-based care in Cardiff. The costs were sensitive to the grade of doctor
(notionally) replaced and the extent of consultant supervision required by the nurse. In conclusion, care based on genetic nurse
counsellors was not significantly different from conventional cancer genetic services in both trial locations.
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Familial cancer is an area in which genetic knowledge has
progressed rapidly over the past 10 years, and where patient
demand for genetics services for information, counselling and
mutation testing has increased dramatically. Even with the
introduction of referral guidelines, regional genetics clinics are
facing the challenge of increasing demand within fixed resources
(Kinmonth et al, 1998), and these difficulties may be exacerbated
as new mutations are identified and further demands are made on
genetics clinics.
Breast cancer is the most common cancer affecting UK women,
resulting in a lifetime risk of one in nine of developing the disease
(Office for National Statistics, 2005). The discovery of breast
cancer susceptibility mutations has attracted widespread publicity
and women with a family history of breast cancer dominate
referrals throughout the UK for any cancer genetic risk counselling
(Wonderling et al, 2001; Hopwood et al, 2004). Mutations in the
known inherited susceptibility genes, BRCA1 and BRCA2, give rise
to increased lifetime risks of developing the disease, often at an
earlier age than sporadic disease (Claus et al, 1994). However,
these mutations are implicated in around only 5–10% of breast
cancer cases, with the result that genetic testing is not appropriate
for the majority of women with a family history of breast cancer.
Genetic counselling services aim to identify individuals who have a
significantly increased genetic risk of cancer and counsel them
about appropriate risk management to reduce morbidity and
mortality (Fry et al, 2003). Access to surveillance, testing and other
interventions is usually dependent on the outcome of the initial
genetic counselling and risk assessment.
Recent research in the area of breast cancer genetic risk
counselling has generally concentrated on women’s psychological
status and risk perception. Evidence from systematic reviews
suggests that genetic counselling does not appear to have any
adverse effect on psychological outcomes (Meiser and Halliday,
2002; Butow et al, 2003; Braithwaite et al, 2004), and may convey
some short-term benefits in decreasing general anxiety and in
improving the accuracy of women’s perceptions of their personal
risk. Historically, clinical genetic risk assessments in the UK have
been conducted largely by medical doctors, with a variable amount
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sof support for genetic counselling provided by genetic nurses and
counsellors, social workers and psychologists as well. Many
specialist centres have recently begun to expand their genetic risk
counselling capacity by recruiting genetic nurses or associates
(Skirton et al, 1998). This trend is likely to continue. However,
there is a lack of formal evaluation of the effectiveness of this
strategy and the lack of well designed and conducted randomised
controlled trials of genetic service models has been noted in a
number of recent publications (Butow et al, 2003; Braithwaite et al,
2004; Hopwood et al, 2004; NICE, 2004).
We therefore conducted a pragmatic evaluation comparing
genetic nurse counsellors as an alternative to a physician-based
service (standard care) in assessing patients newly referred for
genetic counselling for risk of breast cancer. We focused on
patient-centred outcomes, and acceptability to referring general
practitioners, and conducted a concurrent economic evaluation. In
order to increase the generalisability of our findings, we conducted
the evaluation as two randomised controlled equivalence trials
with differing patient population and service characteristics.
MATERIALS AND METHODS
Participants and procedures
Two concurrent randomised controlled trials were conducted to
assess the equivalence of care provided by a genetic nurse
counsellor with clinical geneticist-based (standard) care. The
study locations were the Grampian University Hospitals NHS
Trust Clinical Genetics Service (in Aberdeen) and the Wales
Genetics Service (in Cardiff). The study was designed with a
pragmatic approach; that is, the goal was to gain an insight into the
overall effects of substituting a nurse counsellor-based approach
for a physician-based approach, while accepting that contextual
factors inevitably vary between health care settings. Thus, there
were differences in regular (doctor-based) care in the two trial
locations, but both represented an acceptable ‘standard of care’ for
breast cancer genetic risk assessment and counselling within the
NHS. Similarly, the intervention arms reflected nurse counsellor-
based care developed and managed according to local protocols
and supervisory arrangements. As a clinical geneticist was formally
responsible in each location for patient care, whether it was
delivered by a doctor or a nurse counsellor, we were not concerned
with assessing performance of the nurse counsellors in relation to
technical procedures such as pedigree construction or calculation
of risk estimates. Rather, we concentrated on other outcomes of
interest, including provider and patient satisfaction. By imple-
menting trial procedures rigorously, collecting identical data sets,
but analysing the two trials separately, we were able to promote
internal validity within each trial but also comment on external
validity (i.e. generalisability) (Pocock, 1983).
Patients were eligible if they were newly referred because of
concern about family history of breast cancer, were aged 18 years
or over, and literate in English. Patients previously affected by
breast cancer were included. Patients were excluded if they had
previously attended the genetics clinic or were known to be a
member of a family in which a BRCA1 or BRCA2 mutation had
been previously identified.
Eligible patients were identified from referral letters and consent
to contact was obtained from each patient’s GP. Before their clinic
appointment, patients were sent a letter inviting their participa-
tion, an information sheet explaining the study and a consent
form. Those who consented were randomised to the intervention
(genetic nurse counsellor-based care) or control group (clinical
geneticist-based care). The random allocation schedule sequence
for each trial was computer-generated and concealed within a
Microsoft Access database. To avoid possible contamination,
members of the same family were allocated to the same trial group.
Eligible patients were randomised 2:1 to intervention: control
groups. This uneven allocation was chosen to give greater
experience of the novel intervention and was taken account of in
the sample size calculation. Postal questionnaires were adminis-
tered to participants at baseline (before the clinic appointment),
immediately following the counselling episode (FU1), and 6
months later (FU2).
Standard care in two trial locations (clinical geneticist)
As indicated above, the control arms reflected current standard of
care in each location, and no attempt was made to alter this. The
process for patients referred for genetic assessment was similar in
both centres: family history taking, pedigree construction,
confirmation of cancer diagnoses in affected relatives, risk
assessment, genetic counselling with advice on preventive
strategies and, if appropriate screening, prophylactic surgery,
and/or genetic testing. Initially, the clinical geneticist took the
family history, constructed the pedigree, confirmed cancer
diagnoses, etc in both centres. In Grampian, clerical and nursing
support was available to enable the family tree to be constructed in
advance of the clinic appointment. In Wales the clinical geneticist
did all of the preclinic preparation. In both settings, clinic
appointments involved a clinical geneticist and lasted approxi-
mately 45min.
Intervention (genetic nurse counsellors)
In both trials, the nurse counsellor made the initial contact with
the patient. Each followed the format of the standard care
described above for their own centre, with a nurse counsellor
substituting for clinical geneticist input. Each clinic was therefore
free to make its own organisational arrangements for the nurse-led
counselling arm, so long as there were adequate minimum
supervision arrangements, a clinical geneticist was professionally
and managerially accountable for the patient care delivered by a
nurse counsellor, and the same risk assessment algorithms were
followed within each clinic (by both nurse counsellors and clinical
geneticists). The focus of the study was the ‘counselling episode’:
the time from appointment scheduling until the patient was either
discharged or further management arrangements were made. This
provided the ‘boundary’ to the intervention – all activities from
this point on were part of the ‘usual’ cancer genetics service.
Participants who were considered likely candidates for genetic
testing (i.e. high risk) were referred for further follow-up with a
consultant geneticist. In both trials, a consultant geneticist actively
supervised the nurse counsellors, meeting with them on a weekly
basis. Training was delivered according to the needs of the nurse
counsellors when they were appointed.
Data collection
Sociodemographic data Sociodemographic data were collected
from the women in the baseline questionnaire, and included age,
marital status, number of children, ethnicity and educational level.
Psychological outcomes The primary outcome was patient
anxiety, measured using the six-item short-form of the state scale
of the Spielberger State-Trait Anxiety Inventory (STAI; Marteau
and Bekker, 1992). The short version produces result comparable
with the full state scale and has been used in other genetic
counselling research (Miedzybrodzka et al, 1995; Bish et al, 2002).
We also included the Hospital Anxiety and Depression Scale
(HADS; Zigmond and Snaith, 1983), which gives separate measures
of anxiety and depression assessed over the past week (range of
scores from 0 to 21, seven items for anxiety and seven for
depression).
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sHealth-related quality of life The Short Form 36 (SF-36) health
survey instrument was used to measure perception of general
health status (Ware et al, 1994). It measures patients’ rating of
their own health status in eight areas or domains: physical
functioning, role physical, role emotional, social functioning,
mental health, vitality, bodily pain and general health perception.
For each dimension item scores range from 0 (worst possible
health state) to 100 (best possible health state).
Perceived risk of breast cancer We assessed participants’
perceived risk of breast cancer at all three time points with an
item used in previous research (Lerman et al, 1993; Lloyd et al,
1996; Watson et al, 1999; Brain et al, 2000). Women were asked to
assess their own risk of developing breast cancer relative to a
notional ‘average’ woman, on a five-point scale (‘much lower/
lower/about the same/higher/much higher’). Women previously
affected by breast cancer were asked to skip this section of the
questionnaire to avoid potential confusion.
Knowledge of breast cancer risk factors We assessed participants’
understanding of risk factors for breast cancer at all three time
points. Women were asked how strongly they agreed with three
statements on specific causes of breast cancer (stress, having a
first-degree relative with breast cancer and minor injury). We used
a five-point scale (strongly disagree/disagree/not sure/agree/
strongly agree). For each of these three potential risk factors,
agreement would indicate a response inconsistent with the
education content offered during the genetic counselling appoint-
ment.
Patient satisfaction and acceptability to referring GPs Patient
satisfaction was measured using a modified version of the
Satisfaction with Genetic Counselling Questionnaire developed
by Shiloh et al (1990) and was incorporated into both follow-up
questionnaires. The scale assesses three dimensions of patient
satisfaction: (1) instrumental (satisfaction with the doctor/nurse’s
competence), (2) affective (satisfaction with the doctor/nurse’s
personal qualities) and (3) procedural (satisfaction with adminis-
trative procedures, such as waiting time and staff conduct). The
acceptability of the genetic nurse counsellors to referring GPs was
assessed towards the end of the study. A short questionnaire was
used to ascertain whether the referring GPs had noticed any
difference (including deterioration) in the service provided by the
genetics department for their patients, if they would be happy for
their patients to be seen by a genetic nurse counsellor in the future
and an overall rating of their satisfaction with the genetics services.
Statistical analysis
Descriptive statistics were used to describe the study participants.
As this was an equivalence trial, a confidence interval (CI)
approach was used (Jones et al, 1996). The difference in outcomes
was calculated, adjusting for differences in baseline scores using
multiple linear regression. For each outcome, the 95% CIs around
the difference were calculated. An outcome was considered
‘equivalent’ when the 95% CI for the difference between the
intervention and control group fell completely within a prede-
termined equivalence limit (Jones et al, 1996). Where the 95% CI
for the observed difference fell completely outside the equivalence
limit, we considered the outcomes would be ‘nonequivalent’.
Where the 95% CI for the observed difference overlapped the
equivalence limit, the result would be uncertain. For the primary
outcome, the STAI score, we defined an a priori strict limit of
‘equivalence’ of 74 units (used in the sample size calculation
below), and a ‘likely equivalence’ limit of 710 units (which the
trial steering group considered more reflective of actual clinical
practice). The strict limit was defined before the study started, and
the likely equivalence limit was determined after the study began,
but before data were released for analysis. For anxiety as measured
by HADS, and the role-emotional and mental health domains of
the SF36, we defined the equivalence limit as one-third of a
standard deviation of the baseline scores.
We analysed data using the ‘intention to treat’ principle, in
order to minimise the effect of selection bias and tested the
robustness of the findings by comparing the findings to a
‘treatment-received’ analysis. Analysis was performed using SPSS
v11.0.
Sample size The primary outcome was anxiety as assessed by
STAI (short form), with an equivalence limit of 74 units. We
required 214 participants in the intervention group and 107 in the
control group to allow detection of equivalence (two sided), with
80% power at the 5% significance level. This assumed a standard
deviation of 12 units for STAI (Marteau et al, 1990), and
incorporated the 2:1 allocation ratio.
Economic evaluation
A cost analysis was conducted alongside the trials, adopting a
societal perspective to include health service and patient costs. The
‘cost per patient counselling episode’ for each woman in both trials
was calculated. Data on health service resource use (staff,
consumables, rooms and equipment) were collected and local unit
costs applied where available, otherwise national rates were used.
Staff time included outpatient appointments, preparation, meet-
ings and time in the nurse counsellor arm for consultant
geneticists discussing patient cases with the nurses. The mid-
point of salary scales was used, adding employers’ on-costs at 13%.
An equivalent annual cost was calculated for equipment items such
as computers, over relevant life-spans for the items, using a 6%
discount rate. A total cost per counselling episode for each woman
was calculated by multiplying the unit cost per single appointment
by the number of appointments in each trial arm. Sensitivity
analysis tested the robustness of the findings and data on patient
time and travel costs were also collected. All costs are reported in
Sterling (d) for the price year 2006.
Approval for the study was obtained from the Joint Ethics
Committee of Aberdeen University and Grampian Health Board,
and the research ethics committees of Bro Taf and Iechyd
Morgannwg health authorities.
RESULTS
Participants
Grampian In total, 517 referred patients were considered for
recruitment (Figure 1). Of the 342 (66%) patients who consented
and were randomised (227 intervention, 115 control), 289 (84%)
returned a baseline questionnaire and attended clinic (193 (85%)
intervention, 96 (83%) control). In total, 17 did not receive the
allocated management because of administrative errors (6), joint
family appointments (4) or decision by the head of service (7).
Wales In total, 464 patients were considered for recruitment
(Figure 1). Of the 373 (80%) patients who consented and were
randomised (247 intervention, 126 control), 297 (80%) returned a
baseline questionnaire and attended clinic (197 (80%) interven-
tion, 100 (79%) control). Six women did not receive the allocated
management because of administrative errors (2) and joint family
appointment (4).
Baseline data are presented for women who returned a baseline
questionnaire and attended a clinic appointment (Table 1). The
randomised groups were generally similar in terms of demo-
graphic characteristics. Within each trial, similar proportions of
participants allocated to each arm perceived themselves at elevated
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Grampian Wales
Notes:
a Did not return baseline questionnaire (n=20), did not attend clinic (n=11), moved away (n=1),
subsequently found to be not eligible (n=2).
b Attended appointment with Doctor arm (n=12).
c Did not return baseline questionnaire (n=15), did not attend clinic (n=4).
d Attended appointment with nurse arm (n=4).
Notes:
e Did not return baseline questionnaire (n=39), did not attend clinic (n=10), administrative error (n=1),
subsequently found to be not eligible (n=2).
f Attended appointment with Doctor arm (n=6).
g Did not return baseline questionnaire (n=22), did not attendclinic (n=2), subsequently found to be not
eligible (n=2).
Patients assessed for eligibility (n=517) Patients assessed for eligibility (n=464)
Not randomised (n=91) 
criteria (n=6), no response to recruitment (n=59)
Not randomised (n=175) 
criteria (n=28); no response to recruitment (n=99)
Randomised (n=342)
Allocated to genetic nurse (intervention)
arm (n=227)
Returned baseline questionnaire and
attended clinic (n=193)
a
Received allocated intervention (n=181)b
Allocated to doctor (control) arm (n=115)
Returned baseline questionnaire and
attended clinic (n=96)
c
Received allocated intervention (n=92)d
Immediate follow-up (n=175) 
Lost to follow-up (n=18)
Immediate follow-up (n=83) 
Lost to follow-up (n=13)
Six-month follow-up (n=163) 
Lost to follow-up (n=12)
Completed trial (n=163) Completed trial (n=74) 
Randomised (n=373)
Allocated to genetic nurse (intervention)
arm (n=247)
Returned baseline questionnaire and
attended clinic (n=197)e
Received allocated intervention (n=191)f
Allocated to doctor (control) arm (n=
126)
Returned baseline questionnaire and
attended clinic (n=100)g
Received allocated intervention (n=100)
Immediate follow-up (n=169)
Lost to follow-up (n=27)
Withdrew (n=1)
Immediate follow-up (n=85) 
Lost to follow-up (n=14)
Withdrew (n=1)
Six-month follow-up (n=150)
Lost to follow-up (n=19)
Six-month follow-up (n=73) 
Lost to follow-up (n=12)
Completed trial (n=150)  Completed trial (n=73) 
Six-month follow-up (n=74) 
Lost to follow-up (n=9)
Reasons: refused to take part (n=48); did not fulfil inclusion
Reasons: refused to take part (n=26); did not fulfil inclusion
Figure 1 Progress of participants through the trials.
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srisk, although Wales participants were generally more likely to
view themselves as at elevated risk than Grampian participants.
The actual estimated lifetime risk of breast cancer for participants
only became available after each initial individual counselling
episode was complete. In the Grampian trial, participants in the
intervention arm were more likely than those in the control arm to
be assessed as being at elevated risk, whereas the converse was
observed for the Wales trial. The analysis by treatment received
produced only minor differences in results compared with the
analysis by intention-to-treat, therefore the data are not reported
in this paper.
Anxiety and general health status
Table 2 summarises the primary outcomes for the two trials. There
were small but consistent baseline differences between the
Grampian and Wales study populations, but generally scores were
comparable between intervention and control arms within each
trial. With respect to STAI, all adjusted point estimates for the
differences between intervention and control groups met the
definition of, at least, ‘likely equivalence’.
For anxiety and depression as measured by HADS, a priori
equivalence limits of one-third of the baseline standard deviation
were calculated from the data as 71.4 (Grampian) and 71.5
(Wales) for anxiety and 71.2 (both trials) for depression. These
are close to the smallest possible difference in score for an
individual, which is 71 point. The results of all analyses were
consistent with ‘equivalence’. Also, shown are the observed
differences in the SF36 role-emotional and mental health domains.
The equivalence limits were calculated as 711.4 and 713.1 for the
role-emotional score, and 76.0 and 76.3 for the mental health
Table 1 Characteristics of study participants at baseline
Grampian Wales
Nurse
counsellor Geneticist
Nurse
counsellor Geneticist
No. of patients 193 96 197 100
Age (years): mean
(s.d.)
40.7 (10.3) 41.4 (9.4) 39.8 (10.2) 39.0 (9.3)
Married/cohabiting: n
(%)
151 (80.3) 74 (77.9) 161 (81.7) 84 (84.8)
With children: n (%) 157 (83.5) 73 (76.0) 157 (79.7) 73 (73.0)
Post-secondary
education: n (%)
76 (39.4) 43 (44.8) 73 (37.1) 42 (42.0)
Referral source: n (%)
General
practitioner
133 (68.9) 63 (65.6) 117 (59.4) 56 (56.0)
Breast surgeon 35 (18.1) 19 (19.8) 73 (37.1) 42 (42.0)
Breast screening
clinic
17 (8.8) 10 (10.4) — —
Other 8 (4.1) 4 (4.2) 7 (3.5) 2 (2.0)
n (%) perceiving
themselves to be at
elevated risk at
baseline
130/181
a
(72)
65/91
a (71) 119/ 179
b
(83)
76/90
b (84)
n (%) assessed at
clinic at elevated risk
173/192
c
(90)
74/95
c (78) 145/197
d
(74)
84/100
d (84)
For perceived risk, participants previously affected by breast cancer are excluded:
aSeven nurse counsellor, one geneticist.
b10 nurse counsellor, three geneticist. For
assessed risk, participants previously affected by breast cancer are included:
cFive
nurse counsellor, one geneticist.
d10 nurse counsellor, three geneticist.
Table 2 Psychological outcomes, mean (s.d.)
Grampian Wales
Outcomes
Nurse
counsellor Geneticist
Equivalence
limit
a
Difference
b
(95% CI)
Nurse
counsellor Geneticist
Equivalence
limit
Difference
b
(95% CI)
STAI
c
Baseline 37.3 (13.6) 36.5 (12.8) 40.9 (15.1) 40.0 (14.5)
Immediately after episode 36.4 (14.0) 34.4 (14.0) 74.0 0.8 ( 2.1 to 3.7) 38.1 (14.9) 38.9 (15.6) 74.0  1.5 ( 4.5 to 1.5)
Six months after episode 36.0 (13.5) 32.1 (11.7) 2.9 ( 0.2 to 5.9) 38.9 (14.9) 38.1 (14.1) 0.6 ( 2.9 to 4.1)
HADS
Anxiety
c
Baseline 6.7 (4.3) 6.4 (4.5) 8.1 (4.7) 7.4 (4.2)
Immediately after episode 6.3 (4.3) 5.5 (3.9) 71.4 0.5 ( 0.4 to 1.3) 7.0 (4.9) 7.1 (4.8) 71.5  0.4 ( 1.3 to 0.5)
Six months after episode 6.2 (4.4) 5.5 (3.7) 0.1 ( 0.7 to1.0) 7.4 (4.7) 6.4 (4.1) 0.5 ( 0.6 to 1.5)
HADS
Depression
d
Baseline 3.9 (3.7) 3.4 (3.4) 4.5 (3.7) 4.2 (3.8)
Immediately after episode 3.5 (3.6) 2.9 (2.8) 71.2 0.3 ( 0.4 to 1.0) 4.0 (3.8) 4.0 (3.8) 71.2  0.2 ( 1.0 to 0.5)
Six months after episode 3.4 (3.6) 2.8 (2.9) 0.3 ( 0.5 to 1.0) 4.5 (4.1) 3.9 (3.8) 0.6 ( 0.4 to 1.5)
SF36
Role emotional
e
Baseline 80.5 (34.6) 82.6 (33.4) 74.4 (38.7) 71.0 (40.6)
Immediately after episode 81.6 (35.2) 82.5 (33.2) 711.4 1.9 ( 6.3 to 10.1) 74.8 (39.5) 71.5 (40.0) 713.1 2.9 ( 6.9 to 12.7)
Six months after episode 80.3 (35.9) 86.0 (30.7)  2.5 ( 11 to 5.9) 74.9 (38.7) 73.1 (42.2) 0.5 ( 9.4 to 10.5)
SF36
Mental health
e
Baseline 71.0 (18.2) 73.6 (17.7) 67.3 (18.8) 68.4 (19.3)
Immediately after episode 72.2 (18.6) 74.4 (17.7) 76.0 0.6 ( 2.9 to 4.1) 68.8 (20.5) 68.0 (21.3) 76.3 1.3 ( 2.7 to 5.2)
Six months after episode 72.3 (18.4) 77.4 (14.9)  2.7 ( 6.5 to 1.2) 67.1 (21.1) 67.4 (21.1) 0.3 ( 4.2 to 4.8)
aSet at 74.0 for STAI, 1/3 of baseline s.d.s otherwise.
bAdjusted for baseline.
cHigher score indicates greater level of anxiety.
dHigher score indicates greater level of depression.
eHigher score indicates better health state.
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‘equivalence’ in these outcomes, in both trials, at both follow-up
points, with the exception of the mental health score at the second
follow-up point in the Grampian trial, which indicated that
‘uncertain equivalence’.
Table 3 summarises the SF36 scores for the other health status
outcomes. Scores were generally high, the lowest being observed
for the vitality domain in both trials. On average, higher scores
were observed in all domains in the Grampian trial compared with
the Wales trial.
Patient knowledge
Table 4 summarises the proportions of participants who agreed or
strongly agreed with each statement on a possible cause of breast
cancer. The results are generally similar between the two trial
locations, and between intervention and control arms within each
trial. Misunderstanding was greatest for the effect of having a first-
degree relative with breast cancer. No consistent, or statistically
significant improvements in knowledge were observed for any of
the three notional risk factors.
Table 3 Health related quality of life, SF-36 scores
a: mean (s.d.)
Grampian Wales
Time Nurse counsellor Geneticist Difference (95% CI)
b Nurse counsellor Geneticist Difference (95% CI)
b
Physical functioning
Baseline 88.9 (18.6) 85.4 (21.8) 83.5 (21.8) 88.9 (18.3)
FU1 88.2 (19.1) 88.6 (18.7)  0.5 ( 3.3 to 2.2) 84.9 (20.9) 88.0 (22.5) 0.3 ( 3.7 to 4.3)
FU2 87.9 (18.5) 86.4 (21.3) 0.2 ( 2.3 to 2.7) 84.6 (21.3) 88.6 (20.1)  0.5 ( 5.5 to 4.5)
Social functioning
Baseline 84.0 (23.4) 84.6 (22.1) 77.7 (24.4) 79.8 (26.2)
FU1 83.4 (23.9) 85.2 (21.2)  0.6 ( 5.7 to 4.5) 78.9 (24.8) 79.9 (25.4) 0.3 ( 4.9 to 5.4)
FU2 84.7 (21.8) 87.2 (23.2)  1.0 ( 6.4 to 4.4) 78.0 (26.9) 80.1 (26.4)  1.0 ( 7.6 to 5.5)
Role physical
Baseline 87.1 (29.0) 86.1 (31.3) 81.6 (33.5) 84.9 (30.9)
FU1 86.8 (30.2) 85.1 (32.6) 5.1 ( 1.6 to 11.8)
c 77.4 (37.7) 82.7 (33.4)  3.9 ( 11.4 to 3.6)
FU2 86.0 (30.9) 87.1 (30.3) 1.3 ( 6.1 to 8.7) 77.5 (37.9) 74.0 (38.7) 5.5 ( 4.3 to 15.4)
Vitality
Baseline 58.6 (21.3) 58.5 (23.3) 53.6 (21.1) 54.9 (21.3)
FU1 60.8 (21.7) 61.7 (19.4) 0.5 ( 3.7 to 4.7) 57.1 (22.3) 55.7 (20.3) 2.0 ( 2.3 to 6.3)
FU2 61.6 (20.7) 63.9 (19.0)  1.4 ( 5.7 to 2.9) 55.3 (22.5) 58.3 (21.1)  1.8 ( 7.0 to 3.4)
Bodily pain
Baseline 76.3 (23.9) 76.6 (25.1) 72.3 (25.4) 75.5 (25.0)
FU1 78.6 (24.7) 77.4 (24.4) 2.3 ( 2.4 to 7.1) 75.8 (24.6) 75.8 (26.0)  0.2 ( 5.3 to 4.9)
FU2 78.2 (24.5) 76.1 (23.8) 1.7 ( 3.8 to 7.2) 74.9 (24.9) 75.2 (19.4)  0.2 ( 6.8 to 6.4)
General health
Baseline 73.5 (19.8) 73.4 (18.9) 66.0 (20.6) 71.2 (20.0)
FU1 75.2 (20.7) 74.9 (18.4) 0.8 ( 2.5 to 4.0) 67.9 (21.4) 69.9 (20.7) 1.0 ( 2.4 to 4.3)
FU2 75.0 (18.6) 73.7 (18.5) 1.7 ( 2.0 to 5.4) 68.6 (21.5) 72.5 (19.4)  0.03 ( 3.9 to 3.8)
aHigher score indicates better health state (range 0–100).
bAdjusted for baseline.
cLarger than expected difference due to baseline imbalance of responders at FU1.
Table 4 Respondents indicating ‘Strongly Agree/ Agree’ with statements on causes of breast cancer, n (%)
Grampian Wales
Nurse counsellor Geneticist P-value
a Nurse counsellor Geneticist P-value
a
Stress is a major cause of breast cancer
Baseline 68 (36) 40 (42) 68 (35) 34 (35)
Immediately after episode 80 (47) 39 (48) 0.98 63 (38) 31 (37) 0.98
Six months after episode 71 (42) 31 (44) 0.83 55 (37) 26 (36) 0.91
One close relative with breast cancer always increases your risk considerably
Baseline 157 (83) 77 (81) 165 (84) 80 (83)
Immediately after episode 127 (73) 52 (63) 0.12 130 (77) 65 (77) 0.99
Six months after episode 123 (77) 56 (76) 0.97 122 (81) 58 (80) 0.88
Minor injury can cause breast cancer
Baseline 37 (20) 20 (21) 62 (32) 23 (24)
Immediately after episode 38 (22) 22 (27) 0.50 50 (30) 16 (19) 0.09
Six months after episode 47 (29) 17 (23) 0.39 50 (33) 18 (25) 0.24
aFrom w
2 test (Yates’ corrected – for 2 2 table).
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Figure 2 Patient satisfaction with genetic counselling.
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Clinical StudiesPatient satisfaction
High levels of patient satisfaction were observed in both trials.
Figure 2 shows the views of patients on the specific aspects of
satisfaction with services immediately following the genetic
counselling episode and at the 6 month follow-up point.
Acceptability to referring GPs
In all, 74 and 87 GPs in Grampian and Wales, respectively, referred
at least one patient who was randomised to the nurse counsellor
and who attended the genetic clinic. In all, 68 GPs in Grampian
(response rate 92%) and 75 GPs in Wales (response rate 86%)
responded to the acceptability survey. Grampian respondents, 60
(88%) and 52 (69%) Wales respondents could not differentiate
whether their patient had been seen by a nurse counsellor or a
clinical geneticist. Almost all respondents (Grampian 100%, Wales
98.7% (n¼74)) reported that they would be happy for future
referred patients to be seen at the clinic by the genetic nurse
counsellor. Overall satisfaction with the medical genetics service
was high with 91% (62 out of 68) GPs in Grampian and 89% (67out
of 75). In Wales reporting that they were ‘very satisfied/satisfied’
with the service provided by the respective medical genetics
services.
Economic evaluation The unit costs per counselling appointment
were similar for the clinical geneticist arms in both trials. Cost
differences between intervention and control arms across the two
locations were largely driven by staff costs. For Grampian, the
marginal (additional) cost per single counselling appointment was
d17.98 higher for the control compared with the intervention arm;
in Wales, the marginal cost per counselling appointment was
d12.50 higher for the intervention than the control arm.
Table 5 presents the health service costs per counselling episode.
For Grampian women randomised to the nurse counsellor, the
‘counselling episode’ ranged from 1 to 4 appointments. Most
women received one (149 out of 193, 77%) or two (38, 20%)
appointments. In the control arm, 81 out of 96 (84%) participants
received one, and 13 (13.5%) participants received two, appoint-
ments. The mean cost per patient for the counselling episode was
d136.55 for the nurse counsellor arm and d148.30 for the clinical
geneticist arm, a difference of d11.54 (95% CI, d 25.43, 1.94). In
Wales all participants received one appointment only, hence the
cost per episode and appointment were the same.
Overall, the cost per counselling episode for the nurse counsellor
was d3.55 lower in Grampian compared with Wales, and for the
geneticist arm was d20.70 higher in Grampian than in Wales.
Health service unit costs in both centres appeared sensitive to
grades of staff employed (nurses and doctors), level of supervision
of nurse specialists, and length of counselling appointments, but
not to choice of discount rate or lifespan of equipment items.
DISCUSSION
This study suggests that, for the initial episode of genetic
counselling for risk of breast cancer, nurse counsellors can provide
care that appears to be equivalent to that provided by clinical
geneticists, in terms of patients’ psychosocial outcomes and
satisfaction. The similar findings in the two separate trials support
the generalisability of the findings.
Response rates to the baseline and follow-up surveys were high
and we were able to assess the stability of the outcomes over a 6-
month period following the counselling episode. A high proportion
of eligible patients were recruited into both trials, suggesting that
our study populations were representative of the target popula-
tions. The small but distinct baseline differences between the two
sets of trial participants probably reflect real differences in the
patient populations from which they were drawn. Participants in
Wales had slightly higher anxiety levels overall than the Grampian
participants, but these were balanced between intervention and
control arms within each setting. After genetic counselling, small
reductions in anxiety levels were seen in all groups. Even though
the participants’ baseline mean anxiety scores were slightly higher
than the norm for adult women (score of 35), they were
comparable to anxiety levels found in other studies that have
used the STAI (Cull et al, 1998; Cull et al, 1999; Julian-Reynier
et al, 1999; Brain et al, 2000). The between-trial differences support
the decision to conduct two parallel trials rather than multicentre
trial, where the data would have been pooled (Bowling, 1997).
Comparative data for SF-36 scores for these two general
geographical populations (Garratt et al, 1993; Lyons et al, 1995)
also suggest that our trial participants were slightly more anxious
than the underlying populations, but the between-trial differences
were similar to the background between-population differences. It
is also possible that these apparent differences reflect the different
healthcare referral processes in operation in the two locations. For
example, in Wales, women who were considered to be at increased
familial risk at the breast screening clinic (Breast Test Wales) were
first referred to a surgeon who, after review, made the referral for
genetic counselling. In Grampian, many women were referred
more directly by GPs or other providers to the genetics clinic. It is
possible that these differences in referral pathways contributed to
different anxiety levels in women by the time they received a
genetics clinic appointment, and also influenced their risk
perceptions. Despite these apparent population differences, the
effectiveness data from the two trials were very similar.
Few of the participants in these trials would have been eligible
for genetic testing, and this was not the focus of the study (which
was the period in which initial assessments were made). In both
locations, women who were assessed as suitable for genetic testing
would have been referred to a consultant geneticist for follow-up
care. Our study end point was the point at which a woman learnt of
her risk status, and further follow-up or management arrange-
ments were made. We do not have access to data on how many of
Table 5 Comparison of health service costs per counselling episode
Grampian Wales
Group
Mean number of randomised
appointments (range)
Unit
cost
a
Mean total cost per
patient (d)
Mean number of randomised
appointments (range)
Unit
cost
a
Mean total cost per
patient (d)
Nurse counsellor 1.26 (1–4) 108.01 136.55 1 (1–1) 140.10 140.10
Geneticist 1.18 (1–3) 125.99 148.30 1 (1–1) 127.60 127.60
Difference in cost
(nurse counsellor–
geneticist)
 11.54
b +12.50
aUnit cost of counselling appointment.
b(95% CI, d 25.43, d1.94).
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actual test results.
The primary outcome measure was anxiety, the reduction of which
is regarded as a key counselling objective (Shaw et al, 1999; Brain
et al, 2000; Meiser and Halliday, 2002) and a number of evaluations
of genetic counselling for familial cancer have identified the pre- and
postcounselling assessment of generalised anxiety as a main outcome
measure (Cull et al, 1998, 1999; Julian-Reynier et al, 1999; Brain et al,
2000; Kent et al, 2000; Bish et al, 2002; Bowen et al,2 0 0 4 ) .E v i d e n c e
from systematic reviews suggests that, overall, genetic counselling
has the effect of significantly reducing patients’ anxiety levels, at least
in the short-term (Meiser and Halliday, 2002; Butow et al, 2003;
Braithwaite et al, 2004). The ap r i o r iequivalence limits for the
primary outcome (STAI) were set at a very strict level, and in reality
they probably represent a smaller difference than would normally be
considered clinically significant between two clinicians considered
equally competent; however, results showed that some outcomes
were considered ‘equivalent’ even at this strict level.
Three common mistaken beliefs on the causes of breast cancer
were not influenced by counselling; the most persistent and
erroneously held belief was in the influence of one close relative
with breast cancer on a person’s own risk. This may have reflected
a general misconception, or reflect the participants’ own personal
risk perceptions. The knowledge we assessed was not specific to
cancer genetics, and our findings are consistent with genetic
counselling delivered by either doctors or nurses being equally
effective (or ineffective) in educating patients about breast cancer
risk. Braithwaite et al (2004) suggest that genetic counselling can
be effective in improving knowledge related to breast cancer
genetics, compared with no counselling or counselling delivered by
nongenetics specialists. However, the observed level of misunder-
standing seen in this study suggests that more effective population
interventions are required to improve general knowledge of breast
cancer risks.
Patient satisfaction with information provided, staff attitudes
and the overall clinic procedures were high overall in both trials
irrespective of randomised group. Similar levels of patient
satisfaction have been reported in other trials of genetic
counselling services for risk of breast cancer (Brain et al, 2000;
Hopwood et al, 2004; Holloway et al, 2004). In addition, the
acceptability of the genetic nurses counsellors was high among
referring GPs in both trial settings. However, it is possible that the
difference in service model (i.e. appointment of the nurse
counsellors) may be imperceptible at primary care level as
individual GPs referred only one or two patients during the trial.
The lack of well-designed and rigorously conducted randomised
controlled trials, with reporting to CONSORT standards, in the
field of service delivery for genetic counselling for familial cancer
has been observed in a number of recent publications (Butow et al,
2003; Braithwaite et al, 2004; Hopwood et al, 2004; NICE, 2004).
Alternative models for how nurse counsellors might provide a risk
assessment service include the concept of working in liaison or
outreach settings (Emery et al, 1999; Fry et al, 1999). Two
randomised controlled trials have reported on different models of
service delivery for genetic counselling for risk of breast cancer
(Brain et al, 2000; Fry et al, 2003). In the trial by Brain et al (2000),
the addition of specialist genetic assessment to the standard
surgical consultation had no effect on patients’ psychological
outcomes, risk perception or satisfaction, although knowledge of
cancer genetics showed greater improvement. The other RCT
found community-based genetic nurse specialists to be generally
comparable to the standard service (consultant geneticist), in
terms of psychosocial outcomes and patient satisfaction, with the
additional benefit of lower staff and patient costs (Fry et al, 2003;
Holloway et al, 2004).
There is now an emerging body of research evidence on the
relative effectiveness of nurses in specialist roles compared with
doctors in both primary care (Horrocks et al, 2002), and secondary
care settings (Kinley et al, 2001; Sharples et al, 2002), with most
studies finding that nurses working to guidelines appear to provide
care that is equal to that provided by doctors, with comparable
health outcomes. Previous randomised trials in secondary care
have found nurse practitioners to be either cost neutral (Kinley
et al, 2001) or more expensive than doctors either because of salary
costs (Sakr et al, 2003) or greater resource use (Sharples et al,
2002). In this study, we found that the relative costs of the nurse
counsellors, compared with the doctor-led service, depended on
the grade of medical staff whose time was being replaced by the
nurse counsellor, and the extent of supervision required – of both
nurse counsellors and less experienced medical staff. Surprisingly,
the sensitivity analysis did not suggest that nurse counsellors of
lower grades would be less costly than the nurses employed here,
on the basis that the cost saving in lower salaries would be offset by
the greater need for consultant supervision for nurses at lower
grades.
The results of this study add to the emerging body of evidence
supporting the effectiveness, and possible cost-effectiveness, of
nurse counsellors working under the supervision of consultant
geneticists, and should be taken into account by decision-makers
planning and evaluating genetics health services.
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